Page last updated: 2024-10-22

amiodarone and Triple Negative Breast Neoplasms

amiodarone has been researched along with Triple Negative Breast Neoplasms in 1 studies

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gallyas, F1
Ramadan, FHJ1
Andreidesz, K1
Hocsak, E1
Szabo, A1
Tapodi, A1
Kiss, GN1
Fekete, K1
Bognar, R1
Szanto, A1
Bognar, Z1

Other Studies

1 other study available for amiodarone and Triple Negative Breast Neoplasms

ArticleYear
Involvement of Mitochondrial Mechanisms and Cyclooxygenase-2 Activation in the Effect of Desethylamiodarone on 4T1 Triple-Negative Breast Cancer Line.
    International journal of molecular sciences, 2022, Jan-28, Volume: 23, Issue:3

    Topics: Amiodarone; Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Surviva

2022